For the quarter ending 2026-03-31, JAGX had $2,232K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 8,723 | - | - | - |
| Other comprehensive loss | -458 | - | - | - |
| Net comprehensive income (loss) | 8,265 | - | - | - |
| Provision for inventory obsolescence | - | 2,000 | - | - |
| Loss on extinguishment of debt | -628 | 23 | 0 | -1,822 |
| Depreciation and amortization expenses | 473 | 477 | 479 | 957 |
| Net comprehensive loss | - | -23,186 | -9,781 | -21,441 |
| Changes in fair value of freestanding and hybrid financial instruments designated at fair value option | -337 | -1,545 | -2,310 | -2,411 |
| Interest accrued | 257 | - | - | - |
| Stock-based compensation, vested and released restricted stock units, and exercised stock options | 155 | 116 | 135 | 580 |
| Impairment loss on indefinite-lived intangible assets | - | 800 | - | - |
| Amortization of operating lease - right-of-use asset | 47 | 66 | 78 | 145 |
| Share in joint venture's loss | -9 | -42 | -45 | -75 |
| Amortization of debt issuance costs, debt discount, and non-cash interest expense | - | 153 | - | - |
| Accounts receivable | -1,453 | 84 | 264 | -354 |
| Other receivable | 37 | 108 | -76 | 13 |
| Inventory | -780 | -29 | -91 | 374 |
| Prepaid expenses and other current assets | -231 | -11,529 | 84 | 775 |
| Other assets | -37 | -1,065 | -2 | -106 |
| Accounts payable | -3,755 | 249 | 1,812 | 1,285 |
| Accrued liabilities | 41 | -53 | 528 | 1,581 |
| Deferred revenue | -42 | -43 | -43 | -85 |
| Operating lease liability | -49 | -62 | -73 | -137 |
| Total cash provided by (used in) operating activities | 8,830 | -5,488 | -4,689 | -13,509 |
| Payment of 2025 note payable | 4,000 | - | - | - |
| Payment of convertible notes | 2,435 | 0 | 30 | 20 |
| Payment of insurance financing | 180 | - | - | - |
| Proceeds from convertible notes | 0 | 0 | 0 | 3,445 |
| Purchase of furniture and fixtures | - | -13 | 54 | - |
| Proceeds from issuance of preferred shares in pipe financing, net of issuance cost | - | 0 | 2,377 | - |
| Total cash used in investing activities | - | 13 | -54 | - |
| Proceeds from issuance of common shares/gross proceeds from combined offerings-HCWInvestors | - | - | 1,309 | - |
| Net proceeds-Placement Agent | - | 1,309 | - | - |
| Proceeds from issuance of shares to third party investors | - | - | - | 1,309 |
| Proceeds from new note-Streeterville Capital Llc | - | 10,000 | - | - |
| Net proceeds-Brown Stone Capital Limited | - | 0 | 1,000 | - |
| Proceeds from issuance of shares in at the market offering, net of issuance and offering costs of 0 and 17 in 2026 and 2025, respectively | 0 | -40 | 3,081 | 3,250 |
| Repayment of insurance financing | 0 | 170 | 169 | 313 |
| Payment of tempesta note | 0 | 0 | 0 | 50 |
| Total cash provided by (used in) financing activities | -6,615 | 9,790 | 6,259 | 7,621 |
| Effects of foreign exchange rate changes on assets and liabilities | 17 | -10 | -196 | 93 |
| Net increase (decrease) in cash and restricted cash | 2,232 | 4,305 | 1,320 | -5,795 |
| Cash and restricted cash at beginning of the period | 7,832 | 3,527 | 8,002 | - |
| Cash and restricted cash at end of the period | 10,064 | 7,832 | 3,527 | - |
Jaguar Health, Inc. (JAGX)
Jaguar Health, Inc. (JAGX)